FY2025 EPS Estimates for Zenas BioPharma Boosted by Wedbush

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Wedbush lifted their FY2025 earnings per share (EPS) estimates for shares of Zenas BioPharma in a report issued on Wednesday, November 12th. Wedbush analyst M. Fan now expects that the company will post earnings per share of ($1.25) for the year, up from their previous estimate of ($2.95). Wedbush has a “Outperform” rating and a $45.00 price objective on the stock. Wedbush also issued estimates for Zenas BioPharma’s Q4 2025 earnings at $1.52 EPS, Q1 2026 earnings at ($1.28) EPS, Q2 2026 earnings at ($1.29) EPS, Q3 2026 earnings at ($1.23) EPS, Q4 2026 earnings at ($1.24) EPS, FY2026 earnings at ($5.04) EPS, FY2027 earnings at ($1.46) EPS, FY2028 earnings at ($4.21) EPS and FY2029 earnings at ($2.71) EPS.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

A number of other analysts also recently issued reports on ZBIO. Morgan Stanley raised their price target on shares of Zenas BioPharma from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. HC Wainwright raised their target price on shares of Zenas BioPharma from $30.00 to $44.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Wall Street Zen raised shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Jefferies Financial Group reissued a “buy” rating and set a $52.00 price target on shares of Zenas BioPharma in a report on Monday, October 27th. Finally, Citigroup raised their price target on Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Zenas BioPharma Price Performance

NASDAQ ZBIO opened at $36.21 on Monday. Zenas BioPharma has a one year low of $5.83 and a one year high of $37.89. The stock has a 50-day moving average of $25.89 and a 200 day moving average of $17.47. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -5.12 and a beta of -1.51.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ZBIO. Quarry LP lifted its position in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma during the 3rd quarter worth approximately $30,000. New York State Common Retirement Fund purchased a new position in Zenas BioPharma during the first quarter valued at approximately $49,000. BNP Paribas Financial Markets lifted its holdings in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after purchasing an additional 2,679 shares during the period.

Insiders Place Their Bets

In related news, Director Jason Raleigh Nunn acquired 63,158 shares of Zenas BioPharma stock in a transaction dated Thursday, October 9th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $1,200,002.00. Following the purchase, the director directly owned 1,173,395 shares of the company’s stock, valued at approximately $22,294,505. This trade represents a 5.69% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Hongbo Lu bought 263,160 shares of the firm’s stock in a transaction that occurred on Tuesday, October 7th. The stock was bought at an average cost of $19.00 per share, for a total transaction of $5,000,040.00. Following the completion of the acquisition, the director owned 321,983 shares in the company, valued at $6,117,677. This trade represents a 447.38% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 923,035 shares of company stock valued at $17,628,163. 16.50% of the stock is currently owned by corporate insiders.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.